NCT00321581View on ClinicalTrials.gov

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 1, 2006

Study Completion Date

October 6, 2011

Conditions
Refractory or Recurrent Solid TumorsAcute Myelogenous Leukemia
Interventions
DRUG

Cediranib, AZD2171, RECENTIN

Trial Locations (1)

19104

Childrens Hospital, Philadelphia, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00321581 - AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter